Telmisartan+HCTZ, Hypertension - Full Text View

Telmisartan+HCTZ, Hypertension

This study is currently recruiting participants.
Verified by Boehringer Ingelheim Pharmaceuticals, July 2008

Sponsored by:	Boehringer Ingelheim Pharmaceuticals
Information provided by:	Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00659607

Purpose

This PMS study aims to review the followings by investigating the actual practice of MicardisPlus Tablet on the market:

Condition	Phase
Hypertension	Phase IV

MedlinePlus related topics:

High Blood Pressure

ChemIDplus related topics:

Telmisartan Telmisartan-Hydrochlorothiazide

U.S. FDA Resources

Study Type:	Observational

Official Title:	PMS Study of MicardisPlus Tablet

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Estimated Enrollment:	7000
Estimated Study Completion Date:	February 2009

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:

patients diagnosed as essential hypertension

EXCLUSION CRITERIA:

n/a

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00659607

Contacts


Contact: Boehringer Ingelheim Study Coordinator		clintriage@rdg.boehringer-ingelheim.com

Locations


Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Busan, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Seoul, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Gyeonggido, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Gwangju, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Daegu, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Daejeon, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Chungnam, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Incheon, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Jeju, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Jeonnam, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Jeonbuk, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Ulsan, Korea, Republic of
	Boehringer Ingelheim	Recruiting
	Gangwondo, Korea, Republic of

Sponsors and Collaborators

Boehringer Ingelheim Pharmaceuticals

Investigators


Study Chair:	Boehringer Ingelheim Study Coordinator	B.I. Korea Ltd.

More Information

Study ID Numbers:	502.475
First Received:	April 10, 2008
Last Updated:	July 25, 2008
ClinicalTrials.gov Identifier:	NCT00659607
Health Authority:	Korea, Republic of: KOREA Food and Drug Administration (KFDA)

Study placed in the following topic categories:

Vascular Diseases

Telmisartan

Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 05, 2008